Adalimumab, Infliximab and Etanercept Biosimilars Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Adalimumab, Infliximab and Etanercept Biosimilars Market?
Biosimilars gain an opportunity to penetrate the adalimumab, infliximab, and etanercept biosimilars market with the expiration of patent rights of branded drugs. As an illustration, in the U.S., the FDA granted approval to Inflectra, a product by Hospira (A Pfizer Inc. company), to treat numerous autoimmune conditions like rheumatoid arthritis, adult ulcerative colitis and plaque psoriasis, following the expiration of the patent for the original branded drug, Remicade. Likewise, the patent for Amgen’s Enbrel ended in the EU, leading to the approval of Benepali (an Enbrel biosimilar) by the European Commission. Since Humira’s patent also ran out, its biosimilars have made their way into the market. Additionally, Hulio, sixth in line of Humira biosimilars, has recently received FDA approval. Therefore, the end of patent protection for branded biologic drugs such as Humira, Enbrel, and Remicade will stimulate the demand in the adalimumab, infliximab, and etanercept biosimilars market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
How Will the Growth Rate of theAdalimumab, Infliximab and Etanercept Biosimilars Market Impact Industry Trends by 2034?
The market for biosimilars such as adalimumab, infliximab, and etanercept has seen significant expansion recently. Its size is projected to increase from $4.37 billion in 2024 to $4.98 billion in 2025, equating to a compound annual growth rate (CAGR) of 14.1%. This growth observed in the past can be linked to factors such as higher healthcare spending, regulatory modifications, government measures, and escalating healthcare expenses.
The size of the adalimumab, infliximab, and etanercept biosimilars market is predicted to undergo swift expansion in the coming years, with a projected worth of $7.44 billion by 2029, moving forward at a CAGR of 10.5%. Various factors such as escalating healthcare spending, an aging demographic, and boosted healthcare accessibility are anticipated to propel the market’s growth in the forecast period. During this time, key trends expected to emerge include the launching of novel products, a heightened concentration on mergers and acquisitions, strategic partnerships development, and increased investment endeavors.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473
What Are the Key Market Innovations in theAdalimumab, Infliximab and Etanercept Biosimilars Market Over the Coming Years?
Leading enterprises in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on the creation of novel products, such as citrate-free adalimumab, to deliver consistent services to consumers. This citrate-free adalimumab is a version of the biological drug adalimumab that is devoid of citrate. For example, Fresenius Kabi, a company based in Germany that manufactures medicines and technology for infusion, transfusion, and clinical nutrition, disclosed the FDA approval of its biosimilar Idacio (adalimumab) for dealing with chronic autoimmune disorders in December 2022, covering all approved uses of the original product. This was made possible by employing cutting-edge analytical methods and can be used in managing various chronic diseases.
Who Are the Top Companies Driving Innovation and Growth in theAdalimumab, Infliximab and Etanercept Biosimilars Market?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Adalimumab, Infliximab and Etanercept Biosimilars Market and Drive Its Revenue Growth?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp
Which Regions Are Emerging as Leaders in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2025, By The Business Research Company:
Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Generic Pharmaceuticals Global Market Opportunities And Strategies To 2033
https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-market
Trastuzumab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
